Article: Sanofi-aventis: Encouraging First-Quarter 2008 Results Further Positive Phase III Results for Eplivanserin.

Adjusted EPS excluding selected items:

EURO 1.43, up 1.4%

$2.14, up 15.7%(1)

PARIS, April 30 /PRNewswire-FirstCall/ -- In order to give a representation of our underlying economic performance, we present and explain an adjusted income statement. We also report adjusted net income and adjusted EPS (excluding selected items) in U.S. dollars(1) in order to facilitate comparisons with the majority of major pharmaceutical groups. Consolidated net income for the first quarter of 2008 was EURO 1,325 million, compared with EURO 1,537 million for the first quarter of 2007.

 
  Operating Results 
   * Net sales: EURO 6,937 million, up 0.8% on a ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!